Longevity + SkinResearch-onlyEarly humanUpdated 2026-04-24

Peptide reference file

Selank

Trending #10 in Longevity14.6k searches/moMixed

Selank is a synthetic peptide analog discussed around anxiolytic, cognitive, and neuroimmune signaling themes.

Current readout: early human evidence, research-only status, not approved approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 11765600 | 71 PubMed results | 2 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

Selank is mostly discussed because it is one of the better-known nootropic peptides in online longevity and performance circles.

The public claim is straightforward: It is one of the better-known nootropic peptides in online longevity and performance circles. Early human signal plus a larger surrounding cloud of informal claims.

In plain language, selank is a synthetic peptide analog discussed around anxiolytic, cognitive, and neuroimmune signaling themes.

Early humanResearch-only
Neuropeptide analogAnxiety discussionCognitive interest

Aliases: Thr-Lys-Pro-Arg-Pro-Gly-Pro

SpecimenSelank specimen
CCCCHHHHHHHNO
Formula
C33H57N11O9
Mass
751.9
Evidence
Early human
Elements
4

Most commonly discussed in relation to Neuropeptide analog, Anxiety discussion, Cognitive interest.

What Selank is

Selank is a synthetic peptide analog discussed around anxiolytic, cognitive, and neuroimmune signaling themes.

Selank is grouped under Longevity + Skin / Endogenous / Biology on PeptideFactCheck because it is one of the better-known nootropic peptides in online longevity and performance circles.

The useful starting point is to separate the molecule itself from the internet story around it. It is one of the better-known nootropic peptides in online longevity and performance circles.

Why people keep looking it up

It is one of the better-known nootropic peptides in online longevity and performance circles.

Selank is a synthetic peptide analog discussed around anxiolytic, cognitive, and neuroimmune signaling themes.

Selank tends to stay in the conversation because it touches a familiar public theme: neuropeptide analog, anxiety discussion, and cognitive interest. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Early human signal plus a larger surrounding cloud of informal claims.

Some human literature exists, but the evidence base is still narrower than the confidence of internet discussion.

The peptide is mainly supported by smaller studies and mechanistic neurobiology narratives.

Why this page carries the current tier: Early human signal plus a larger surrounding cloud of informal claims.

The current seed trail for Selank is pulling from 1 literature source, 1 trials source, and 1 databases source.

Safety, limits, and regulatory context

Claims about mood, cognition, and performance are easy to oversell when the evidence remains limited.

Selank is not FDA-approved in the current record.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Selank. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Selank is CID 11765600. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
11765600
Formula
C33H57N11O9
Molecular weight
751.9
InChIKey
JTDTXGMXNXBGBZ-YVHUGQOKSA-N

Matched synonyms include Selank, 129954-34-3, Selanc, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TS9JR8EP1G, L-Proline, L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-, Threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline, DTXSID701029276.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Selank returns 2 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Selank returns 71 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.